摘要
目的:探讨多肿瘤标志物蛋白芯片中糖链抗原CA125对恶性肿瘤的诊断价值方法:收集第三军医大学大坪医院可供分析的25 076例多肿瘤蛋白芯片检测结果,分析CA125在不同人群、不同肿瘤中升高情况,以及CA125升高伴随其他检测指标升高在肿瘤中的分布情况。结果:CA125在恶性肿瘤患者中明显高于良性病变患者及正常体检者,而且卵巢癌最高(51.92%),其次为胰腺癌(49.25%)和肝癌(42.56%);同时升高的指标以CEA最为常见,其次为CA199、CA242和Ferritin,CA125/CEA同时升高最常见于结直肠癌(83.87%),其次为乳腺癌(59.72%),CA125/CA199同时升高最常见于结直肠癌(90.97%)和胰腺癌(78.63%),CA125/CA242伴随升高最常见于结直肠癌(92.26%)和胰腺癌(74.81%),CA125+CEA+CA199及CA125+CEA+CA199+CA242升高均最常见于肺癌。结论CA125单项指标升高对卵巢癌、胰腺癌及肝癌的诊断有较高的价值,CA125伴随或联合CEA、CA199、CA242检测有利于提高结直肠癌、胰腺癌、肺癌的诊断阳性率。
Objective： To investigate the expression of carbohydrate antigen 125 （ CA125 ）, its association with other markers, and their clinical significance in a variety of populations using protein chip detective systems. Methods： A total of 25,076 cases detect- ed with multiple tumor marker chips from 2004 to 2011 were collected. The expression levels of CA125 and its association with other markers were analyzed in various populations and patients with different types of tumor. Results： CA125 expression was significantly elevated in patients with malignant tumors compared with patients with benign disease and healthy individuals. The CA125 positive rate appeared to be the highest in ovarian cancer （ 59.72% ）, followed by that in pancreatic （ 49.25% ） and liver （ 42.56% ） cancers. The most common accompanying marker was CEA; other less common markers were CA199, CA242, and ferritin. The CA125/CEA combination occurred most frequently in colorectal cancer （ 83.87% ） followed by breast cancer （59.72%）. CA125/CA199 was most prevalent in colorectal （90.97%） and pancreatic （ 78.63% ） cancers. CA125/CA242 frequently appeared in colorectal （ 92.26% ） and pancreatic （ 74.81% ） cancers. CA125＋CEA＋CA199 and CA125＋CEA＋CA199＋CA242 increase were most common in lung cancer. Conclusion： Elevated CA 125 is a good indicator of ovarian, pancreatic, and liver cancers. The detection of CA125 combined with CEA, CA 199, and CA242 has significance in improving the diagnosis of colorectal, pancreatic, and lung cancers.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第9期607-610,共4页
Chinese Journal of Clinical Oncology
